Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT02443077 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

94

Enrollment

NIH

Sponsor class

Conditions

Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type

Interventions

PROCEDURE: Autologous Bone Marrow Transplantation
PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation
DRUG: Carmustine
DRUG: Cyclophosphamide
DRUG: Cytarabine
DRUG: Etoposide
DRUG: Ibrutinib
OTHER: Laboratory Biomarker Analysis
DRUG: Melphalan
OTHER: Pharmacogenomic Study
OTHER: Placebo Administration

Sponsor

National Cancer Institute (NCI)